U.S. Biotech Firm Generate Biomedicines Raises $400 Mln in IPO

Dow Jones

Feb 27

By Jason Chau

Generate Biomedicines has announced the pricing of its initial public offering, implying a market value of about $2 billion for the U.S. biotechnology firm.

The company, which specializes in designing and developing drugs using artificial intelligence, raised $400 million from selling 25 million shares at $16.00 each.

Shares are expected to start trading on Friday, with the public offering set to close on March 2.

Generate has granted underwriters a 30-day option to purchase up to an additional 3.75 million shares.

In September, the Somerville, Mass.-based company said it had raised nearly $700 million in equity financing since 2020, including $273 million from a Series C funding round backed by investors such as Nvidia's venture capital arm.

Goldman Sachs and Morgan Stanley are acting as joint lead book-running managers for the IPO.

Write to Jason Chau at jason.chau@wsj.com

(END) Dow Jones Newswires

February 27, 2026 00:44 ET (05:44 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2614788589"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614788589\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614788589?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 13:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614788589","market":"other","top_or_hot":-1,"title":"U.S. Biotech Firm Generate Biomedicines Raises $400 Mln in IPO","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Jason Chau \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/GENB\">Generate Biomedicines</a> has announced the pricing of its initial public offering, implying a market value of about $2 billion for the U.S. biotechnology firm. \n</p>\n<p>\n  The company, which specializes in designing and developing drugs using artificial intelligence, raised $400 million from selling 25 million shares at $16.00 each. \n</p>\n<p>\n  Shares are expected to start trading on Friday, with the public offering set to close on March 2. \n</p>\n<p>\n  Generate has granted underwriters a 30-day option to purchase up to an additional 3.75 million shares. \n</p>\n<p>\n  In September, the Somerville, Mass.-based company said it had raised nearly $700 million in equity financing since 2020, including $273 million from a Series C funding round backed by investors such as <a href=\"https://laohu8.com/S/NVDA\">Nvidia</a>'s venture capital arm. \n</p>\n<p>\n  Goldman Sachs and Morgan Stanley are acting as joint lead book-running managers for the IPO. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Jason Chau at jason.chau@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 27, 2026 00:44 ET (05:44 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. Biotech Firm Generate Biomedicines Raises $400 Mln in IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. Biotech Firm Generate Biomedicines Raises $400 Mln in IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-27 13:44</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Jason Chau \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/GENB\">Generate Biomedicines</a> has announced the pricing of its initial public offering, implying a market value of about $2 billion for the U.S. biotechnology firm. \n</p>\n<p>\n  The company, which specializes in designing and developing drugs using artificial intelligence, raised $400 million from selling 25 million shares at $16.00 each. \n</p>\n<p>\n  Shares are expected to start trading on Friday, with the public offering set to close on March 2. \n</p>\n<p>\n  Generate has granted underwriters a 30-day option to purchase up to an additional 3.75 million shares. \n</p>\n<p>\n  In September, the Somerville, Mass.-based company said it had raised nearly $700 million in equity financing since 2020, including $273 million from a Series C funding round backed by investors such as <a href=\"https://laohu8.com/S/NVDA\">Nvidia</a>'s venture capital arm. \n</p>\n<p>\n  Goldman Sachs and Morgan Stanley are acting as joint lead book-running managers for the IPO. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Jason Chau at jason.chau@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 27, 2026 00:44 ET (05:44 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2357305700.SGD","symbol_name":"Allianz Global Artificial Intelligence ET H2-SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2614788589","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614788589","pubTimestamp":1772171040,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Generate Biomedicines has announced the pricing of its initial public offering, implying a market value of about $2 billion for the U.S. biotechnology firm.The company, which specializes in designing and developing drugs using artificial intelligence, raised $400 million from selling 25 million shares at $16.00 each.Shares are expected to start trading on Friday, with the public offering set to close on March 2.Generate has granted underwriters a 30-day option to purchase up to an additional 3.75 million shares.In September, the Somerville, Mass.-based company said it had raised nearly $700 million in equity financing since 2020, including $273 million from a Series C funding round backed by investors such as Nvidia's venture capital arm.Goldman Sachs and Morgan Stanley are acting as joint lead book-running managers for the IPO.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU1548497426.USD":"安联环球人工智能AT Acc","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LABU":"三倍做多标普生物-Direxion","LU0106831901.USD":"贝莱德世界金融基金A2","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU0882574139.USD":"富达环球消费行业基金A ACC","BK4581":"高盛持仓","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","GENB":"Generate Biomedicines","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","BK4127":"投资银行业与经纪业","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4516":"特朗普概念","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","BK4504":"桥水持仓","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0557290698.USD":"施罗德环球可持续增长基金","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","BK4588":"碎股","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU0971096721.USD":"富达环球金融服务 A","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)"},"translate_title":"美国生物技术公司Generate Biomedicines IPO融资4亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GENB":1.5,"LABU":1.5},"content_text":"By Jason Chau \n\n\n \n\n\nGenerate Biomedicines has announced the pricing of its initial public offering, implying a market value of about $2 billion for the U.S. biotechnology firm. \n\n\n  The company, which specializes in designing and developing drugs using artificial intelligence, raised $400 million from selling 25 million shares at $16.00 each. \n\n\n  Shares are expected to start trading on Friday, with the public offering set to close on March 2. \n\n\n  Generate has granted underwriters a 30-day option to purchase up to an additional 3.75 million shares. \n\n\n  In September, the Somerville, Mass.-based company said it had raised nearly $700 million in equity financing since 2020, including $273 million from a Series C funding round backed by investors such as Nvidia's venture capital arm. \n\n\n  Goldman Sachs and Morgan Stanley are acting as joint lead book-running managers for the IPO. \n\n\n \n\n\n  Write to Jason Chau at jason.chau@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 27, 2026 00:44 ET (05:44 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}